Kageleiry A - Search Results

1

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.

Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M. Kimball AB, et al. Among authors: kageleiry a. Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11. Br J Dermatol. 2014. PMID: 25040429 Clinical Trial.

2

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.

Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Swallow E, et al. Among authors: kageleiry a. Curr Med Res Opin. 2014 Aug;30(8):1537-45. doi: 10.1185/03007995.2014.908829. Epub 2014 Apr 14. Curr Med Res Opin. 2014. PMID: 24669852

3

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.

Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H. Campone M, et al. Among authors: kageleiry a. J Med Econ. 2014 Dec;17(12):837-45. doi: 10.3111/13696998.2014.959589. Epub 2014 Sep 18. J Med Econ. 2014. PMID: 25164472 Free article.

4

Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.

Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guérin A. Li N, et al. Among authors: kageleiry a. Curr Med Res Opin. 2016;32(2):385-94. doi: 10.1185/03007995.2015.1130691. Curr Med Res Opin. 2016. PMID: 26651842

5

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J. Cadranel J, et al. Among authors: kageleiry a. Lung Cancer. 2016 Aug;98:9-14. doi: 10.1016/j.lungcan.2016.05.004. Epub 2016 May 10. Lung Cancer. 2016. PMID: 27393500

6

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.

Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K. Lim SH, et al. Among authors: kageleiry a. Asia Pac J Clin Oncol. 2017 Oct;13(5):e239-e245. doi: 10.1111/ajco.12645. Epub 2017 Apr 16. Asia Pac J Clin Oncol. 2017. PMID: 28419723

7

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. Guérin A, et al. Among authors: kageleiry a. Cancer Epidemiol. 2015 Jun;39(3):307-12. doi: 10.1016/j.canep.2015.04.005. Epub 2015 Apr 23. Cancer Epidemiol. 2015. PMID: 25914136

8

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.

Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Guérin A, et al. Among authors: kageleiry a. Expert Opin Pharmacother. 2016 Jun;17(9):1189-96. doi: 10.1080/14656566.2016.1176148. Epub 2016 Apr 21. Expert Opin Pharmacother. 2016. PMID: 27052735

9

Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.

Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guérin A. Li N, et al. Among authors: kageleiry a. J Med Econ. 2016;19(4):414-23. doi: 10.3111/13696998.2015.1131704. J Med Econ. 2016. PMID: 27032967 Free article.

10

Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.

Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A. Hao Y, et al. Among authors: kageleiry a. Adv Ther. 2016 Jun;33(6):983-97. doi: 10.1007/s12325-016-0328-3. Epub 2016 May 23. Adv Ther. 2016. PMID: 27216253

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page